文献速递头痛与眩晕

靶向降钙素基因相关肽的偏头痛药物:药理学如何指导治疗决策

Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions.
PubMed 文献 · Lancet Neurol · 2022-01-31

本文综述了针对降钙素基因相关肽(CGRP)的两类偏头痛药物——gepants(CGRP受体拮抗剂)和针对CGRP或其受体的单克隆抗体的药理学及临床效应。文章指出,性別、体重指数、年龄、种族背景等特征可能影响这些疗法的药代动力学,尤其是gepants,若研究证实,这些特征可帮助临床医生为偏头痛患者选择最佳治疗。选择gepant或单克隆抗体应谨慎,需考虑患者的合并症和偏好。

要点

  • gepants和CGRP单克隆抗体两类药物已可用于偏头痛治疗。
  • 性別、体重指数、年龄、种族背景等可能影响药代动力学,尤其对gepants。
  • 选择gepant或单克隆抗体需考虑患者合并症和偏好。

核心结论

  • 对CGRP靶向疗法的药理学和临床效应认识仍不足,试验数据不一定能推广到所有人群。
  • 性別、体重指数、年龄、种族背景等特征可能影响这些疗法的药代动力学,尤其是gepants。
  • 若研究证实,这些特征可帮助临床医生为偏头痛患者选择最佳治疗。
  • 选择gepant或单克隆抗体应谨慎,需考虑患者的合并症和偏好。
  • 随着对CGRP靶向疗法认识的增加,基于患者特征的管理可能在偏头痛治疗中发挥更突出作用。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • gepants(CGRP受体拮抗剂)和针对CGRP或其受体的单克隆抗体自2018年起已可用于临床。
  • 性別、体重指数、年龄、种族背景等特征可能影响这些疗法的药代动力学,尤其是gepants。
  • gepants和CGRP单克隆抗体影响的若干药效学过程尚未完全清楚。

临床怎么用

  • 选择gepant或单克隆抗体应谨慎,需考虑患者的合并症和偏好。
  • 基于患者特征的管理可能在偏头痛治疗中发挥更突出作用。

局限性

  • 对这些药物的药理学和相关临床效应认识仍不足。
  • 试验数据不一定能推广到所有人群。
  • gepants和CGRP单克隆抗体影响的若干药效学过程尚未完全清楚。
  • 性別、体重指数、年龄、种族背景等特征可能影响药代动力学,这一可能性尚需研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Migraine is the second most disabling disorder across all age groups worldwide. Since 2018, two classes of drugs that inhibit the actions of calcitonin gene-related peptide (CGRP), which is implicated in migraine pathophysiology, have become available: gepants (CGRP receptor antagonists) and monoclonal antibodies directed against CGRP or its receptor. Despite phase 3 clinical trials and some real world evidence, knowledge of the pharmacology and related clinical effects of these drugs is low, and trial data are not necessarily generalisable to all populations. Additionally, several pharmacodynamic processes affected by both gepants and monoclonal antibodies to CGRP and its receptor are not fully understood. Sex, body-mass index, age, ethnic background, and other characteristics, which are subject to considerable variation, might affect the pharmacokinetics of these therapies, especially gepants. If studies confirm this possibility, these characteristics could assist clinicians in choosing the optimal treatment for patients with migraine. The choice between a gepant or monoclonal antibody should be made carefully, taking into consideration a patient's comorbidities and preferences. As more becomes known about CGRP-targeted therapies, management based on the characteristics of patients could have a more prominent role in the treatment of migraine.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Al-Hassany L, Goadsby PJ, Danser AHJ, et al. Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol. 2022. PMID: 35093196. doi:10.1016/S1474-4422(21)00409-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。